Drug General Information
Drug ID
D0HT2X
Former ID
DIB005594
Drug Name
CNT0-1959
Drug Type
Antibody
Indication Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] Phase 2 [551042]
Company
Janssen biotech
Target and Pathway
Target(s) Interleukin-23 ligand Target Info [533191]
KEGG Pathway Cytokine-cytokine receptor interaction
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Jak-STAT signaling pathway
Type I diabetes mellitus
Pertussis
Legionellosis
Leishmaniasis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Toxoplasmosis
Amoebiasis
Tuberculosis
Measles
Influenza A
Herpes simplex infection
Inflammatory bowel disease (IBD)
Allograft rejection
WikiPathways Toll-like receptor signaling pathway
Aryl Hydrocarbon Receptor Pathway
Allograft Rejection
Regulation of toll-like receptor signaling pathway
References
Ref 551042Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy in Treatment of Moderate to Severe Plaque Psoriasis. Janssen Research & Development, LLC (Janssen). Mar 24, 2014.
Ref 533191Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.